In January 2025, AstraZeneca (NASDAQ:AZN)'s two innovative cancer therapies have been approved by the FDA; DATROWAY and combination of CALQUENCE with bendamustine and rituximab.
Datroway (datopotamab deruxtecan-dlnk) is a treatment for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have previously undergone endocrine-based therapy and the second is the combination of CALQUENCE (acalabrutinib) with bendamustine and rituximab to treat previously untreated mantle cell lymphoma (MCL) in adult patients who are ineligible for autologous stem cell transplantation.
The efficacy for the first therapy reached 37% reduction in the risk of compared to chemotherapy. And the second therapy demonstrated a 27% reduction in disease progression or death risk compared to standardchemoimmunotherapy. When excluding COVID-19-related deaths, the risk reduction improved to 36%.
The approval of CALQUENCE in the U.S. marks the first and only BTK inhibitor approved for first line MCL treatment and provides a critical treatment option to patients with this rare and aggressive form of non-Hodgkin lymphoma.
With these approvals, AstraZeneca works to lead advancements in treating complex and-life threatening cancers and provide patients with more treatment options to them.
The revenue of AstraZaneca has grown at a 3-year CAGR of 15.4% and Datroway marks the eighth new medicine of its targeted twenty medicines by 2030, with more revenue streams we can project higher income to be generated by AstraZaneca.
Published: January 20, 2025
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。